It is very uncertain whether probiotics changes minor adverse events compared with placebo (very low certainty).
It is very uncertain whether probiotics changes minor adverse events compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (very low certainty).
It is very uncertain whether probiotics changes serious adverse events compared with placebo (very low certainty).
It is very uncertain whether probiotics changes serious adverse events compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (very low certainty).
It is very uncertain whether probiotics changes adverse events compared with placebo (very low certainty).
Probiotics showed no clear difference in adverse events compared with control (low certainty).
It is very uncertain whether probiotics changes adverse Events: complete case compared with control (very low certainty).
Probiotics showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).
It is very uncertain whether probiotics changes withdrawal due to adverse events compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (very low certainty).
It is very uncertain whether probiotics changes withdrawals due to adverse events compared with magnesium oxide (very low certainty).
It is very uncertain whether probiotics changes serious adverse events (52 weeks) compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (very low certainty).
It is very uncertain whether probiotics changes adverse events leading to withdrawal compared with placebo (very low certainty).
It is very uncertain whether probiotics changes withdrawal due to adverse events (52 weeks) compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (very low certainty).
It is very uncertain whether probiotics changes serious adverse events compared with control (very low certainty).